Antares Pharma Inc. (ATRS)
-NasdaqCM | Prev Close: | 4.10 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 5.80 |
|---|
| Beta: | 0.42 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 3.35 - 5.58 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 966,670 |
|---|
| Market Cap: | 517.32M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.13 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Identifying the Biggest Gem in Antares's Pipelineat Motley Fool(Thu, Jun 13)
- Subcutaneous, Self-Administered Methotrexate for Rheumatoid Arthritis Demonstrated Significantly Greater Bioavailability over Current Standard of CareBusiness Wire(Thu, Jun 13)
- Wednesday's Biotech Catalyst Trade Watch Listat Seeking Alpha(Wed, Jun 12)
- 4 Top Small Cap Biotech Acquisition Targetsat Seeking Alpha(Fri, May 31)
- Antares Pharma Inc. Presents at 38th Annual Deutsche Bank Health Care Conference, May-30-2013 10:40 AMat Seeking Alpha(Thu, May 30)
- Antares Pharma to Present at the Jefferies 2013 Global Healthcare ConferenceBusiness Wire(Wed, May 29)
- ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote oEDGAR Online(Tue, May 28)
- Antares Pharma to Present at the Deutsche Bank Securities, Inc. 38th Annual Health Care ConferenceBusiness Wire(Fri, May 24)
- Antares Pharma Welcomes Marvin Samson to Board of DirectorsBusiness Wire(Thu, May 23)
- Long-Term Biotech: 3 Names To Discover Nowat Seeking Alpha(Tue, May 21)
- 2013 FDA Drug Approval Calendarat TheStreet(Tue, May 21)
- SmithOnStocks Opines On Stocks: May 19th Editionat Seeking Alpha(Sun, May 19)
- 3 Most Important Upcoming FDA Decisions of 2013at Motley Fool(Fri, May 17)
- Finding Value in the Medical Products and Device Spaces: An Experienced Portfolio Manager Discusses Investing in Overlooked Health Care AreasWall Street Transcript(Fri, May 17)
- Antares: Reiteration Of My Buy Recommendationat Seeking Alpha(Thu, May 16)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| ATRS | 0.00% | 517.32M |
| BAX | 0.00% | 38.41B |
| COV | 0.00% | 31.02B |
| CSRT.L | 0.00% | 228.42M |
| BDX | 0.00% | 19.50B |
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 25.56 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.12 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.03 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies, and topical gel-based medicines worldwide.
View More